Skip to main content

Table 2 Linear regression analysis with log-transformed serum CGRP-LI levels (mol/l) T0

From: Serum CGRP in migraine patients using erenumab as preventive treatment

Variable β (95% CI)1 p β (95% CI)2 p
Age 0.07 (-0.001–0.13) 0.05 0.07 (0.004–0.14) 0.04
Sex 1.92 (-0.41–4.25) 0.10 2.50 (0.17–4.82) 0.04
Migraine days baseline 0.09 (-0.06–0.24) 0.24 0.11 (-0.04–0.26) 0.14
Serum CGRP-LI -1.033 (-2.37–0.30) 0.13 -0.80 (-2.16–0.55) 0.24
 N = 94. 1Simple linear regression. 2multiple regression, corrected for all tested variables. CI = confidence interval. T0 = baseline, before starting treatment with erenumab. The outcome is absolute reduction migraine days during month 3 after starting treatment with erenumab compared to baseline. One month is defined as 28 days.